Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Sep 1;51(9):1124-1137.
doi: 10.1097/CCM.0000000000005883. Epub 2023 Apr 20.

Atrial Fibrillation (AFIB) in the ICU: Incidence, Risk Factors, and Outcomes: The International AFIB-ICU Cohort Study

Collaborators, Affiliations
Multicenter Study

Atrial Fibrillation (AFIB) in the ICU: Incidence, Risk Factors, and Outcomes: The International AFIB-ICU Cohort Study

Mik Wetterslev et al. Crit Care Med. .

Abstract

Objectives: To assess the incidence, risk factors, and outcomes of atrial fibrillation (AF) in the ICU and to describe current practice in the management of AF.

Design: Multicenter, prospective, inception cohort study.

Setting: Forty-four ICUs in 12 countries in four geographical regions.

Subjects: Adult, acutely admitted ICU patients without a history of persistent/permanent AF or recent cardiac surgery were enrolled; inception periods were from October 2020 to June 2021.

Interventions: None.

Measurements and main results: We included 1,423 ICU patients and analyzed 1,415 (99.4%), among whom 221 patients had 539 episodes of AF. Most (59%) episodes were diagnosed with continuous electrocardiogram monitoring. The incidence of AF was 15.6% (95% CI, 13.8-17.6), of which newly developed AF was 13.3% (11.5-15.1). A history of arterial hypertension, paroxysmal AF, sepsis, or high disease severity at ICU admission was associated with AF. Used interventions to manage AF were fluid bolus 19% (95% CI 16-23), magnesium 16% (13-20), potassium 15% (12-19), amiodarone 51% (47-55), beta-1 selective blockers 34% (30-38), calcium channel blockers 4% (2-6), digoxin 16% (12-19), and direct current cardioversion in 4% (2-6). Patients with AF had more ischemic, thromboembolic (13.6% vs 7.9%), and severe bleeding events (5.9% vs 2.1%), and higher mortality (41.2% vs 25.2%) than those without AF. The adjusted cause-specific hazard ratio for 90-day mortality by AF was 1.38 (95% CI, 0.95-1.99).

Conclusions: In ICU patients, AF occurred in one of six and was associated with different conditions. AF was associated with worse outcomes while not statistically significantly associated with 90-day mortality in the adjusted analyses. We observed variations in the diagnostic and management strategies for AF.

PubMed Disclaimer

Conflict of interest statement

The Department of Intensive Care, Rigshospitalet, has received funds for other research projects from the Novo Nordisk Foundation, Sygeforsikringen “danmark,” Pfizer, and Fresenius Kabi, and does contract research for AM-Pharma. The Department of Intensive Care, Copenhagen University Hospital—North Zealand, has received funds for other research projects from the Novo Nordisk Foundation, Sygeforsikringen “danmark,” and other foundations and does contract research for AM-Pharma and Inotrem. Dr. Bestle has received consultancy fee from AM-Pharma. Dr. Wetterslev received funding from The Research Council of Rigshospitalet, The Ehrenreich’s Foundation, and The Danish Society of Anesthesiology and Intensive Care Medicine; he received support for article research from The Research Council of Rigshospitalet, Copenhagen, Denmark. Drs. Granholm’s and Bestle’s institutions received funding from Sygeforsikringen. Dr. Granholm’s institution received funding from The Ehrenreich’s Foundation, the Novo Nordisk Foundation, Pfizer, Fresenius Kabi, and AM-Pharma. Drs. Shen, Gao, and Yang disclosed work for hire. Dr. Bestle received funding from AM-Pharma. Dr. Haranath received funding from Medvarsity. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Comment in

Similar articles

Cited by

References

    1. Chugh SS, Roth GA, Gillum RF, et al.: Global burden of atrial fibrillation in developed and developing nations. Glob Heart. 2014; 9:113–119
    1. Hindricks G, Potpara T, Dagres N, et al.; ESC Scientific Document Group: 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42:373–498
    1. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 1991; 22:983–988
    1. Odutayo A, Wong CX, Hsiao AJ, et al.: Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: Systematic review and meta-analysis. BMJ. 2016; 354:i4482
    1. Clark DM, Plumb VJ, Epstein AE, et al.: Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. 1997; 30:1039–1045

Publication types